| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Introduction
|
|
Editorial
|
page S1
|
| Tumour immunology |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
CD4+ and DC requirements for optimal CD8+ CTL induction against tumors
|
Cornelis JM Melief,
Danita Schuurhuis,
Linda Diehl,
Jan Paul Medema,
Ferry Ossendorp,
Robert S. Mittler,
René Toes,
Rienk Offringa
et al.
|
Abstract
|
page S5
|
|
|
rViscumin, a novel anticancer agent — preclinical and clinical development status
|
K. Wilhelm-Ogunbiyi,
B. Möckel,
A. Burger,
M. Langer,
H. Zinke,
H.H. Fiebig,
H. Lentzen
et al.
|
Abstract
|
page S5
|
|
|
Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow
|
M. Feuerer,
P. Beckhove,
L. Bai,
E.-F. Solomayer,
G. Bastert,
I.J. Diel,
V. Schirrmacher,
V. Umansky
et al.
|
Abstract
|
page S5
|
|
|
Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells
|
Thomas Decker,
Christian Peschel
|
Abstract
|
page S5
|
|
|
Immune deficiencies in breast cancer
|
C. Wiltschke,
A. Budinsky,
C. Kichler-Lakomy,
CC. Zielinski
|
Abstract
|
page S6
|
|
|
Generation of HER2-reactive T helper and T killer cells: implementation for T cell therapy
|
Helga Bernhard,
Christian Meyer zum Büschenfelde,
Burkhard Schmidt,
Jochen Metzger,
Christian Peschel
et al.
|
Abstract
|
page S6
|
|
|
Immune restoration in cancer patients by cyclooxygenase-inhibition in vitro and in vivo
|
S. Lang,
B. Wollenberg,
B. Schmitt,
C. Clausen,
I. Löhr,
L. Lauffer,
O. Gires,
R. Zeidler
et al.
|
Abstract
|
page S9
|
|
|
Expression of cytokine receptors on AML blasts
|
M. Graf,
S. Danhauser-Riedl,
C. Schoch,
S. Schnittger,
T. Haferlach,
W. Hiddemann,
H. Schmetzer
et al.
|
Abstract
|
page S9
|
|
|
Low CD62L- expression in acute myeloid leukemia (AML) correlates with a bad cytogenetic risk
|
M. Graf,
S. Danhauser-Riedl,
S. Schnittger,
C. Schoch,
T. Haferlach,
W. Hiddemann,
H. Schmetzer
et al.
|
Abstract
|
page S9
|
|
|
In vitro-generation of potent antigen-presenting cells for immunotherapy: IL-4 is more effective than IFN-α
|
M. Dauer,
K. Pohl,
T. Meskendahl,
M. Schnurr,
S. Endres,
A. Eigler
et al.
|
Abstract
|
page S9
|
|
|
A novel strategy for the identification by phage panning in vivo of ligands specific for cells in the extra-vascular space
|
A.N. Finger,
M. Bisoffi,
A. Wetterwald,
E. Gautschi,
U. Hohenfeld,
I. Klima,
G.N. Thalmann,
B.M. Stadler,
M.G. Cecchini
et al.
|
Abstract
|
page S10
|
|
|
Inactivation of the INK4 gene cluster in mantle cell lymphomas - standardization and initial analysis of differential methylation patterns of cell cycle regulators
|
G. Hutter,
G. Herzog,
Y. Zimmermann,
E. Göcke,
J. Lu-Hesselmann,
W. Hiddemann,
M. Dreyling
et al.
|
Abstract
|
page S10
|
|
|
Staphylococcal enterotoxin B- mediated T cell immune response induces apoptosis in bladder cancer cells
|
Patricia L. Willert,
Frank G.E. Perabo,
Andreas Wirger,
Berthold Amann,
Doris H. Schmidt,
Eva Wardelmann,
Stefan C. Müller
et al.
|
Abstract
|
page S10
|
|
|
In-vitro TNF-α effects on hematopoietic cell lines
|
V Jurisic,
G Bogdanovic,
T Srdic,
N Kraguljac,
M Baltic,
V.V. Baltic
et al.
|
Abstract
|
page S10
|
|
|
Peroxisome proliferator activated receptor γ (PPARγ) agonists for treatment of neoplastic diseases - in vitro data and early clinical observations in chronic myelomnocytic leukemia (CMML) and in liposarcoma
|
C. Denzlinger,
A. Möhle,
F. Machicao,
R. Möhle,
P. Brossart,
H.-U. Häring,
L. Kanz,
K. Dittmann
et al.
|
Abstract
|
page S11
|
|
|
Multicellular gastric cancer spheroids represent a valid model for pre-clinical testing of new therapeutic strategies
|
B. Mayer,
G. Klement,
M. Kaneko,
S. Jothy,
R.S. Kerbel
et al.
|
Abstract
|
page S11
|
|
|
Magnetic drug targeting: biokinetic study and therapeutic efficacy
|
Ch. Alexiou,
P. Hulin,
R. Klein,
A. Schmidt,
Ch. Bergemann,
F.G. Parak,
W. Arnold
et al.
|
Abstract
|
page S11
|
|
|
Apoptosis resistance and immune escape mechanisms of bladder cancer cells
|
Patricia L. Willert,
Frank G.E. Perabo,
Stefan Kamp,
Doris H. Schmidt,
Andreas Wirger,
Peter Albers,
Stefan C. Müller
et al.
|
Abstract
|
page S11
|
|
|
Selective cytotoxicity of a diphtheria toxin-interleukin-3 fusion protein on acute myeloid leukemia stem cells
|
M. Feuring-Buske,
A. Frankel,
R. Alexander,
G. Gerhard,
D. Hogge
et al.
|
Abstract
|
page S12
|
|
|
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma
|
Michael Huhn,
Stephanie Sasse,
Mehmet K. Tur,
T. Schinköthe,
Susanna M. Rybak,
Andreas Engert,
Stefan Barth
et al.
|
Abstract
|
page S12
|
|
|
Assessing the cancerostatic potency of rViscumin towards human tumor xenografts and cell lines in vitro
|
B. Möckel,
A. Burger,
R.J. Schultz,
K. Wilhelm-Ogunbiyi,
M. Langer,
H. Zinke,
H.H. Fiebig,
H. Lentzen
et al.
|
Abstract
|
page S12
|
|
|
Systemic tumor regression mediated by effector T cells generated from perforin/IFN-γ double knock out mice is TNF dependent
|
C.H. Poehlein,
H.-M. Hu,
J. Yamada,
I. Assmann,
R. Hatz,
W.J. Urba,
B.A. Fox,
R.W. Franz
et al.
|
Abstract
|
page S12
|
|
|
The use of anti-CD3/CD28-dynabeads to restimulate human antigen specific T cells or expand naïve T cells
|
Anne-Marie Rasmussen,
Anne Rian,
Kari Lislerud,
Ingvil Sæterdal,
Gustav Gaudemack,
Marianne K. Gjertsen
et al.
|
Abstract
|
page S13
|
|
|
Biological tumour regression and dormancy: a new therapetic approach from tumour stability analysis
|
Prasun K Roy,
Jaydeep Biswas
|
Abstract
|
page S13
|
|
|
Hsp70-peptide activated autologous NK cells in the immunotherpay of cancer — a clinical pilot study
|
S. Krause,
R. Magerstädt,
G. Thonigs,
R. Andreesen,
H-J. Kolb,
T. Haferlach,
C. Schoch,
S. Schnittger,
W. Hiddemann,
G. Multhoff
et al.
|
Abstract
|
page S13
|
|
|
Our finding that the GvM and GvH effect are caused -at least partly- by different cell clones allows for the first time a selective GvM potentiation without a parallel GvHD induction
|
P. Leskovar,
R. Schmidmaier
|
Abstract
|
page S13
|
|
|
A strong and rapid immunosuppression by extracellular ROS- cleaving enzymes (GSH-peroxidase, catalase, MnSOD, CuZnSOD) gives evidence for a permanent, O2illegible??? and O22− maintained intercellular cross talk, even in the resting state ROS- cleaving enzymes as novel immunosuppressants and HO2 and H2O2 as well as NH3 and polyamines as novel “second messengers”
|
P. Leskovar,
A. Dickelhuber,
R. Schmidmaier,
K. Abdalla,
M. Graw
et al.
|
Abstract
|
page S14
|
|
|
Our novel approaches (A) in the prevention of the acute and chronic graft-versus-host disease (GvHD) and — even more important — (B) in the eradication of pre-established GvHD could help to introduce clinically a variety of adoptive immunotherapies
|
P. Leskovar,
R. Schmidmaier
|
Abstract
|
page S14
|
|
|
Establishment of a stable mixed allogeneic chimerism by the successive injection of a 1:1 mixture of mature, lifespan-preprogrammed donor plus recipient T cells or PBMCS, followed by a 1:1 mixture of immature, non-DNA-premanipulated bone marrow or stem cells of the same donor : host origin
|
P. Leskovar,
R. Schmidmaier
|
Abstract
|
page S14
|
|
|
Two important improvements of the conventional BMT and HSCT: (A) the routine use of a 1:1 mixture of D- and R- derived BMCS (or HSCS) preceded by the 1:1 mixture of D- and R- derived MIS effectors, and (B) the routine use of haploidentical MIS effectors, combined with BMT or HSCT
|
P. Leskovar,
R. Schmidmaier
|
Abstract
|
page S14
|
|
|
New chances for a renaissance of the HSCT- supported high-dose chemotherapy by the actively prevented tolerance-reinduction against inevitable residual tumor cells in the critical early phase of the treatment-related immuno-incompetence
|
P. Leskovar,
R. Schmidmaier
|
Abstract
|
page S15
|
|
|
Tumor therapy : a gradual replacement of myeloablative preparative regimens by non-ablative ones reflects the recent trend towards an indirect, immunoregulatory intervention instead of the direct attack on the tumor cells. Some important clinical implications of our extensive animal experiments
|
P. Leskovar,
R. Schmidmaier
|
Abstract
|
page S15
|
|
|
Induction of an effective immune response against tumor-cell-spheroids induced by the trifunctional antibody BiUIII (anti-EpCAM X anti-CD3)
|
A. Walz,
B. Mack,
B. Schmitt,
B. Wollenberg,
R. Zeidler
et al.
|
Abstract
|
page S15
|
| Anticancer vaccines |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Vaccination with T cell-defined antigens: biological basis and clinical applications
|
Giorgio Parmiani
|
Abstract
|
page S19
|
|
|
Specific vaccination based on the Her2/neu proto-oncogene
|
Rolf Kiessling,
Jan-Alvar Lindencrona,
Jehad Charo,
Christina Hising,
Giuseppe Masucci,
Max Petersson,
Jonas Bergh,
Lars Franksson
et al.
|
Abstract
|
page S19
|
|
|
Applications of CpG oligonucleotides in cancer therapy
|
Gunther Hartmann
|
Abstract
|
page S19
|
|
|
Identification of new immunogenic antigens in acute and chronic myeloid leukemias (AML / CML) for the development of vaccines
|
Michael Schmitt
|
Abstract
|
page S19
|
|
|
Recent advances in idiotype vaccination for the treatment of non-Hodgkin's lymphoma
|
Hendrik Veelken
|
Abstract
|
page S20
|
|
|
Naked DNA and viral vectors as tumor vaccines
|
Gabriele Pecher
|
Abstract
|
page S20
|
|
|
Results of a phase II HPV vaccine trial with life recombinant vaccinia virus TA-HPV™
|
AM Kaufmann,
EM Rankin,
H Sommer,
V. Nuessler,
A Schneider,
M Adams,
HC Kitchener,
T Bauknecht,
U Wagner,
K Kroon,
J Hickling,
CM Boswell,
S Stacey,
P Stern,
J Gillard,
J Wanders,
Jst J. Roberts,
H Zwierzina
et al.
|
Abstract
|
page S20
|
|
|
Novel gene delivery systems
|
Jeffrey Ulmer
|
Abstract
|
page S20
|
|
|
Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells
|
Thomas Decker,
Christian Peschel
|
Abstract
|
page S21
|
|
|
CpG ODNs enhance recall and prmary specific human CTL responses
|
V. Hornung,
S. Rothenfusser,
S. Britsch,
A. Towarowski,
S. Endres,
D. Speiser,
G. Hartmann
et al.
|
Abstract
|
page S25
|
|
|
CpG ODNs enhance recall and prmary specific human CTL responses
|
V. Hornung,
S. Rothenfusser,
S. Britsch,
A. Towarowski,
S. Endres,
D. Speiser,
G. Hartmann
et al.
|
Abstract
|
page S25
|
|
|
Membrane expression of heat shock protein 70 (Hsp70) in hematological malignancies
|
M Gehrmann,
M Hantschel,
K Pfister,
R Gastpar,
R Andreesen,
H Schmetzer,
T Haferlach,
S Schnittger,
C Schoch,
H-J Kolb,
W Hiddemann,
G Multhoff
et al.
|
Abstract
|
page S25
|
|
|
Expression of HLA-class I and II molecules is maintained on leukemic blasts from patients with acute myelogenous leukemia (AML) and the costimulatory molecule CD 86 is upregulated
|
M. Vollmer,
A. Eil,
S. Hübsch,
A. Szmaragowska,
L. Bergmann,
H. Döhner,
M. Schmitt
et al.
|
Abstract
|
page S25
|
|
|
Vaccination with peptides derived from the extracellular domain of Her-2/neu elicits specific humoral and cellular immune responses in mice
|
J. Jasinska,
T. Brodowicz,
S. Wagner,
U. Wiedermann,
C. Radauer,
R Sedivy,
M. Kubista,
H. Breiteneder,
Ch. Wiltschke,
O. Scheiner,
C.C. Zielinski
et al.
|
Abstract
|
page S26
|
|
|
Her-2 expression is of independent prognostic significance in pNO prostate cancer undergoing curative radiotherapy
|
A. Fosså,
W. Lilleby,
S.D. Fosså,
G. Gaudernack,
G. Torlakovic,
A. Berner
et al.
|
Abstract
|
page S26
|
|
|
Vaccination with modified HER-2 molecules containing potent helper T cell epitopes induces protective immune responses in HER-2 transgenic mice
|
D.R. Leach,
L. Sonderbye,
V. Renard,
K. Ebbehøj,
K. Gregorius,
P. Birk,
A. Gautam,
S. Mouritsen
et al.
|
Abstract
|
page S26
|
|
|
Intradermal ras peptide vaccination of colorectal cancer patients: a randomized trial of two different dose levels of mutant ras peptides with- or without GM-CSF
|
Marianne K. Gjertsen,
Jan Petter Paulsen,
Steinar Aamdal,
Ingvil Sæterdal,
Jon A. Eriksen,
Møller Mona,
Eva Vognild,
Ragnhild Lothe,
Gustav Gaudernack
et al.
|
Abstract
|
page S26
|
|
|
Mechanism of tumor eradication by transfer of sensitized T cells
|
S. Shu,
P.A. Cohen
|
Abstract
|
page S27
|
|
|
A TGFβRII frameshift mutation derived CTL epitope recognised by HLA-A2 restricted CD8+ T cells
|
Ingvil Sæterdal,
Marianne K. Gjertsen,
Per thor Straten,
Gustav Gaudernack
|
Abstract
|
page S27
|
|
|
T cell polarization in tumor vaccine draining lymph nodes (TVDLN) correlates with the tumor immunogenicity
|
H. Winter,
H-M. Hu,
R. Hatz,
F.W. Schildberg,
B.A. Fox
et al.
|
Abstract
|
page S27
|
|
|
Induction of T cell immune response after DNA immunization with human cytochrome P450 CYP1B1 — a potential cancer therapy
|
Urban Ramstedt,
Chistine Barbon,
Lisa Moore,
Richard Parent,
Mary Lynne Hedley,
Goeffrey Cole
et al.
|
Abstract
|
page S27
|
|
|
Effective immunotherapy of large established tumors with CpG oligonucleotides and dendritic cells in murine tumor models
|
K. Rall,
K. Heckelsmiller,
A. Schlamp,
S. Endres,
G. Hartmann
et al.
|
Abstract
|
page S28
|
|
|
Effective immunotherapy of large established tumors with CpG oligonucleotides and dendritic cells in murine tumor models
|
K. Rall,
K. Heckelsmiller,
A. Schlamp,
S. Endres,
G. Hartmann
et al.
|
Abstract
|
page S28
|
| Dendritic cells |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Monocyte-derived dendritic cells to induce immunity to cancer
|
G. Schuler
|
Abstract
|
page S31
|
|
|
Heat shock proteins and dendritic cells: effects on maturation and antigen presentation
|
M. Kuppner,
V. Milani,
R. Gastpar,
E. Noessner,
M. Roos,
R. Issels
et al.
|
Abstract
|
page S31
|
|
|
Immunotherapy of malignant diseases with peptide pulsed dendritic cells
|
Peter Brossart
|
Abstract
|
page S31
|
